There is a long tradition, particularly in parts of Europe and Asia, of ingesting microbes or food products that affect the intestinal microbiota in ways that are believed to provide beneficial health effects, i.e. intake of probiotics and prebiotics. According to the World Health Organization, probiotics are defined as viable microorganisms that confer a health benefit when administered in sufficient doses.

A few studies have revealed that probiotic *Lactobacillus* strains were useful in reducing gingival inflammation and the number of black-pigmented rods, including *Porphyromonas* *gingivalis* (*Pg*), in the saliva and subgingival plaque ([@CIT0001]--[@CIT0003]). Concerning periodontal conditions, Teughels and coworkers ([@CIT0004]) have shown that application of beneficial bacteria, as an adjunct to scaling and root planing (SRP), can inhibit recolonization of pathogens in periodontal pockets and reduce bleeding on probing in dogs. Another clinical trial demonstrated a reduced prevalence of moderate to severe gingival inflammation as well as an improved Plaque Index (PI) and probing depth in adults after regular use of probiotic tablets ([@CIT0005]). Also, probiotic chewing gums consumed over the course of 2 weeks caused a reduction in proinflammatory cytokines in gingivitis patients ([@CIT0006]).

On the other hand, mechanical debridement by SRP is one of the basic periodontal treatment procedures known to reduce periodontal inflammatory effects ([@CIT0007]--[@CIT0009]). A Medline search using the key words 'CGP' (chronic generalized periodontitis), 'SRP,' and 'Probiotics' revealed a lack of data on Gingival Index (GI) and Gingival Bleeding Index (GBI) reduction after SRP along with probiotics in the treatment of periodontal disease. To date, the combination of SRP and probiotics has not been addressed as a treatment protocol for periodontal patients. Hence, to determine the effects of probiotics in periodontitis cases, we conducted a double blind, randomized, placebo-controlled clinical trial in patients with chronic periodontitis.

Material and methods {#S0001}
====================

This was a randomized, placebo-controlled, double blind, split-mouth designed clinical study to evaluate the effect of probiotic lozenges with and without SRP on the clinical parameters and microbiological profile in subgingival plaque samples of chronic periodontitis patients.

To calculate the proper sample size, the change in probing depth at the end of 42 days was estimated to be 0.1 mm in the test group. The sample size was calculated to be approximately 15 subjects each in the test and placebo groups with a power of 0.80 and α at 0.05.

Patients of both sexes within the age limit of 35--50 years were eligible for inclusion. Patients diagnosed as suffering from chronic periodontitis as clinically evidenced by gingivitis together with mild to moderate periodontal pockets (5--7 mm) clinically and radiographic evidence of bone loss were included ([@CIT0010]). Apart from having chronic periodontitis, the patients were in general good health and had not participated in any clinical trial during the previous 4 weeks. No patient had ongoing antibiotic treatment or any systemic disease. Patients who were pregnant, lactating, smokers, alcoholic, or who had undergone any surgical or non-surgical therapy within 6 months prior to the start of the study were not included. Written informed consent was obtained from all patients.

All subjects were assigned to one of the two groups (Prodentis group or placebo group) by using a randomization table. To maintain full blinding of the results, the randomization code was held by one of the authors remotely from all assessments and was not broken until all data had been collected and all analyses had been performed. The randomization was concealed by using sequentially numbered, identical-appearing containers of probiotic or placebo tablets.

Clinical and microbiological parameters were recorded at baseline (day 0), on day 21, and day 42. The clinical parameters recorded were PI ([@CIT0011]), GI ([@CIT0012]), GBI ([@CIT0013]), probing pocket depth (PPD), and clinical attachment level (CAL) ([@CIT0014]). PPD and CAL were measured for the indexed teeth of the Community Periodontal Index using the WHO probe ([@CIT0014]). All parameters were assessed by a single clinical investigator experienced with the index systems. Patients were given *Lactobacillus reuteri* Prodentis (containing a minimum of 1×10^8^ colony forming units (CFU) for each of the strains DSM17938 and ATCC PTA 5289 (Prodentis)). Both study products, Prodentis and placebo lozenges, were identical in shape, texture, and taste. The patients were instructed to take suck lozenge by sucking in the morning and one at night, after brushing their teeth ([@CIT0002]). The lozenges were administered to the patients from day 21 after the clinical and microbiological parameters had been assessed and continued until day 42.

Split-mouth SRP in all patients was achieved by treating two quadrants with SRP on day 0 while two quadrants were left untreated. SRP was performed using ultrasonic (Cavitron® -- BOBCAT PRO, DENTSPLY; Power-240AC 50/60Hz 80VA) and hand instruments (Universal Gracey Curettes, 2R/2L and 4R/4L Hufriedy). After SRP, the patients were instructed to perform regular oral hygiene habits, i.e. twice daily brushing by 'roll-on technique' for a minimum of 2 min, using a regular toothpaste (STOLIN-R® Dr. Reddy\'s Lab) and regular toothbrushes (Stim® toothbrush -- DentAids Pvt. Ltd.), which were provided to each subject.

After recording the clinical parameters, at least 10--12 sites with 5--7 mm pocket depth were selected for subgingival pooled plaque sample collection separately for each half of the mouth. The pooled plaque samples were collected at baseline and on day 21 and day 42 from the same sites. The sample site was isolated with sterile cotton rolls and the supragingival plaque was removed using cotton rolls and air dried. A sterile curette was introduced to the base of the pocket and plaque was removed. The curette with the collected plaque was dispensed in separate vials containing transport media viz. thioglycolate broth with hemin and Vit k (transport 8 medium) and sealed tightly to avoid contamination. Samples were processed within 2 days of collection. The sample was mixed thoroughly and 5µl aliquots were was inoculated using a sterile loop onto petri plates with the following mediums: enriched trypticase soy agar for *Aggregibacter actinomycetemcomitans* (*Aa*) cultivation ([@CIT0015]); kanamycin blood agar for *Pg* ([@CIT0016]); and kanamycin and vancomycin blood agar for *Prevotella intermedia* (*Pi*) ([@CIT0016]). The samples were then vortexed at 3000×*g* for 1 min to break the plaque and to obtain uniform dispersal of organisms.

The plates were kept under anaerobic conditions. The medium for *Aa* was incubated in a desiccator with 5% carbon dioxide at 37°C for 5 days. The plates were incubated for a minimum of 72 h. After the specified period, the colonies were characterized according to size, shape, hemolysis, and pigmentation and the number of each colony type was counted.

*Aa* was identified by its characteristic star-shaped colonies on the agar plate, Gram negative coccobacillary morphology, negative indole test, nitrate reduction, and glucose fermentation. *Porphyromonas* and *Prevotella* species were provisionally identified by pigment production, colony characters, cell morphology, and the variation in their susceptibility to kanamycin and vancomycin. The identity of these organisms was further confirmed by subjecting them to a series of biochemical reactions, which included indole production, nitrate reduction, and sugar fermentation tests. The sugars tested were dextrose, mannitol, lactose, sucrose, maltose, salicin, glycerol, xylose, arabinose, trehalose, rhamnose, and xylan. A uniform standardized suspension of the organisms was prepared in thioglycollate broth and inoculated into peptone yeast extract broth containing 1% of the appropriate sugar and bromocresole purple as the indicator. The tubes were incubated for 48 h in a modified gas-pak anaerobic jar and the fermentation reactions were noted by a change in the color of the indicator to yellow. Indole and nitrate reduction tests were performed by spot disc method using commercially available reagents (Hi-Media).

All clinical and microbiologic data collected were subjected to statistical analysis. Results are expressed as mean±SD and proportions as percentages. For clinical parameters, intra-group comparisons were made by paired *t*-test and inter-group comparison by unpaired *t*-test. For microbiological parameters, non-parametric methods were used for analysis since microbes were non-normally distributed; the Wilcoxon\'s signed rank test was used for intra-group comparison and the Mann--Whitney test for inter-group comparison. For all tests a *p*-value of less than 0.05 was considered statistically significant.

The study protocol was in accordance with the local ethical guidelines and in accordance with the Helsinki Declaration of Human Rights and approved by the local ethics committee.

Results {#S0002}
=======

Thirty, systemically healthy, chronic periodontitis patients (19 males and 11 females, aged between 34 and 50 years) were included. Age, gender distribution, clinical and microbiological parameters were similar in both groups at day 0 (baseline) ([Table 1](#T0001){ref-type="table"}). All subjects completed the 42-day study period. There were no significant differences in the clinical and microbiological parameters between the Prodentis and placebo groups at day 0.

###### 

Baseline characteristics of study participants (mean (SD))

                        Prodentis group   Placebo group   Significance
  --------------------- ----------------- --------------- --------------
  Men/women             9/6               10/5            ns
  Age (years)           41.4 (5.3)        41.5 (4.9)      ns
  PI (score)            1.79 (0.36)       1.77 (0.20)     ns
  GI (score)            1.85 (0.22)       1.88 (0.12)     ns
  GBI (%)               81.6 (18.4)       87.9 (13.5)     ns
  PPD (mm)              5.08 (0.75)       5.26 (0.53)     ns
  CAL (mm)              3.93 (0.93)       4.46 (1.94)     ns
  *Aa* (CFU/ml×10^4^)   105.3 (66.8)      103.0 (66.4)    ns
  *Pg* (CFU/ml×10^4^)   89.7 (70.4)       98.7 (60.4)     ns
  *Pi* (CFU/ml×10^4^)   81.0 (67.0)       80.3 (73.1)     ns

The active study product of Prodentis lozenges was re-analyzed by the producer (BioGaia AB, Sweden) at the end of the study and the CFU count of both strains was above the stipulated shelf-life limit of 1×10^8^ CFU. The presence of lactobacilli in the saliva, plaque, or gingival pockets was not assessed in this study.

Within both the Prodentis and the placebo groups, with or without SRP, PI, GI, or GBI, the reduction was highly significant (*p*\<0.001) over the treatment periods ([Fig. 1](#F0001){ref-type="fig"}). The maximum reduction of PI (0.76±0.29) was obtained for the combination of SRP and Prodentis, which was statistically significant when compared to all other treatment modalities (*p*\<0.01) ([Table 2](#T0002){ref-type="table"}). In the untreated quadrants, Prodentis was significantly better than the placebo with a reduction of 0.41±0.16 and 0.17±0.14, respectively (*p*\<0.001). Also for the GI and GBI, the best reduction was obtained with the combination of SRP and Prodentis as compared with the other treatment modalities (*p*\<0.001), the GI fell from 1.85±0.22 to 1.01±0.10 and the GBI from 81.6±18.4 to 11.1±4.6% over the full period. In the untreated quadrants, Prodentis was better than the placebo on both accounts, the GI was reduced by 0.53±0.12 and 0.14±0.14 units (*p*\<0.001) and the GBI by 48.3±14.4 and 12.0±8.7 percentage units (*p*\<0.001), respectively. An interesting observation was that Prodentis alone demonstrated a highly significant (*p*\<0.001) GBI reduction as compared to SRP alone.

![Results of the clinical assessments during the study period. Error bars indicate SD. ![](JOM-2-5344-i001.jpg) =Prodentis group; ![](JOM-2-5344-i002.jpg) =placebo group.](JOM-2-5344-g001){#F0001}

###### 

Statistical comparison (unpaired *t*-test) of the clinical effects between the treatment modalities after 42 days (values are given as mean (SD))

  Group            Reduction     Group         Reduction      Significance
  ---------------- ------------- ------------- -------------- --------------
  PI score                                                    
   SRP+Prodentis   0.76 (0.29)   SRP+placebo   0.27 (0.13)    *p*\<0.001
   SRP+Prodentis   0.76 (0.29)   Prodentis     0.41 (0.16)    *p*\<0.001
   SRP+placebo     0.27 (0.13)   Placebo       0.17 (0.14)    *p*\<0.05
   Prodentis       0.41 (0.16)   Placebo       0.17 (0.14)    *p*\<0.001
  GI score                                                    
   SRP+Prodentis   0.84 (0.23)   SRP+placebo   0.38 (0.23)    *p*\<0.001
   SRP+Prodentis   0.84 (0.23)   Prodentis     0.53 (0.12)    *p*\<0.001
   SRP+placebo     0.38 (0.23)   Placebo       0.14 (0.14)    *p*\<0.01
   Prodentis       0.53 (0.12)   Placebo       0.14 (0.14)    *p*\<0.001
  GBI (%)                                                     
   SRP+Prodentis   70.4 (10.7)   SRP+placebo   32.5 (10.0)    *p*\<0.001
   SRP+Prodentis   70.4 (10.7)   Prodentis     48.3 (14.4)    *p*\<0.001
   SRP+placebo     32.5 (10.0)   Placebo       12.0 (8.7)     *p*\<0.001
   Prodentis       48.3 (14.4)   Placebo       12.0 (8.7)     *p*\<0.001
  PPD (mm)                                                    
   SRP+Prodentis   1.31 (0.49)   SRP+placebo   0.49 (0.39)    *p*\<0.001
   SRP+Prodentis   1.31 (0.49)   Prodentis     0.10 (0.20)    *p*\<0.001
   SRP+placebo     0.49 (0.39)   Placebo       −0.04 (0.23)   *p*\<0.001
   Prodentis       0.10 (0.20)   Placebo       −0.04 (0.23)   ns
  CAL (mm)                                                    
   SRP+Prodentis   1.09 (0.62)   SRP+placebo   0.29 (0.51)    *p*\<0.001
   SRP+Prodentis   1.09 (0.62)   Prodentis     0.17 (0.26)    *p*\<0.001
   SRP+placebo     0.29 (0.51)   Placebo       −0.05 (0.26)   *p*\<0.05
   Prodentis       0.17 (0.26)   Placebo       −0.05 (0.26)   *p*\<0.05

In the untreated quadrants, the PPD was only slightly changed after the placebo or Prodentis treatment, however these changes were not significant either over time or between groups. Over the 42 days, SRP alone significantly reduced PPD from 5.26±0.53 to 4.77±0.60 mm (*p*\<0.001). The maximum PPD reduction was observed in SRP+Prodentis treatment from 5.08±0.75 to 3.78±0.61 mm, which was significantly better than SRP alone (*p*\<0.001).

The CAL did not change significantly over time in the untreated quadrants group receiving placebo whereas there was a small decrease in the corresponding Prodentis group from 3.85±1.44 to 3.67±1.31 mm (*p*\<0.05), which was also better than for the placebo group (*p*\<0.05). The SRP+placebo treatment yielded a decrease from 4.46±1.94 to 4.17±1.82 mm (*p*\<0.05). Again, the best result was obtained for the combination of SRP+Prodentis where the CAL dropped from 3.93±0.93 to 2.85±0.74 mm (*p*\<0.001). This was also better than any other treatment modality (*p*\<0.001).

The only treatment modalities that were able to significantly reduce the CFU counts of the pathogens *Aa*, *Pg*, and *Pi* were those including Prodentis, either alone or in combination with SRP ([Table 3](#T0003){ref-type="table"} and [Fig. 2](#F0002){ref-type="fig"}). All three pathogens were equally sensitive toward Prodentis treatment and bacterial counts were reduced by approximately 1 log~10~ unit from 10^6^ CFU/ml to less than 10^5^ CFU/ml.

![Results of the microbiological assessments during the study period. Error bars indicate SD. ![](JOM-2-5344-i003.jpg) =Prodentis group; ![](JOM-2-5344-i004.jpg) =placebo group.](JOM-2-5344-g002){#F0002}

###### 

Statistical comparison (Wilcoxon\'s signed rank test) of the microbiological effects between the treatment modalities after 42 days (values are given as mean (SD) CFU/ml×10e4).

  Group            Reduction     Group         Reduction      Significance
  ---------------- ------------- ------------- -------------- --------------
  Aa                                                          
   SRP+Prodentis   94.0 (62.8)   SRP+placebo   6.4 (75.7)     *p*\<0.005
   SRP+Prodentis   94.0 (62.8)   Prodentis     74.7 (67.9)    ns
   SRP+placebo     6.4 (75.7)    Placebo       10.0 (21.0)    ns
   Prodentis       74.7 (67.9)   Placebo       10.0 (21.0)    *p*\<0.01
  Pg                                                          
   SRP+Prodentis   85.7 (73.5)   SRP+placebo   0.4 (46.4)     *p*\<0.005
   SRP+Prodentis   85.7 (73.5)   Prodentis     91.3 (51.7)    ns
   SRP+placebo     0.4 (46.4)    Placebo       −6.8 (32.3)    ns
   Prodentis       91.3 (51.7)   Placebo       −6.8 (32.3)    *p*\<0.001
  Pi                                                          
   SRP+Prodentis   77.0 (65.1)   SRP+placebo   6.4 (67.9)     *p*\<0.05
   SRP+Prodentis   77.0 (65.1)   Prodentis     71.0 (63.6)    ns
   SRP+placebo     6.4 (67.9)    Placebo       −16.4 (69.2)   ns
   Prodentis       71.0 (63.6)   Placebo       −16.4 (69.2)   *p*\<0.001

Compliance to the study treatment was appreciable and no subject rejected using the lozenges. Hypersensitivity as a symptom of root caries was not reported by any of the study subjects and no other adverse reactions were reported by the subjects or observed by the clinician during the study period.

Discussion {#S0003}
==========

The effect of SRP as a non-surgical mode of periodontal therapy is well discussed in the literature in terms of a reduction of clinical and microbial parameters. According to a review in 2009 ([@CIT0017]), the basic/initial treatment for periodontal patients in terms of SRP has not been compared with the probiotic effect in the reduction of clinical and microbiological parameters. Hence, an initial attempt has been made in this randomized, double blind clinical trial to evaluate and compare the benefits of the probiotic Prodentis alone and SRP+Prodentis in the treatment of chronic periodontitis.

In both the Prodentis and the placebo groups, PI, GI, and GBI were significantly reduced within each treatment group over the 42 days and thus even the placebo, with or without SRP, had a significant effect. However, such placebo effects are known to occur as a simple consequence of the contact between clinicians and patients ([@CIT0018], [@CIT0019]) and that they were instructed on proper brushing technique when the study started.

The effect of SRP on plaque reduction is similar to that reported by Mousquès et al. ([@CIT0009]) and Proye et al. ([@CIT0020]). Mousquès reported the reduction of PI and GI during the first 14 days after a single mouth SRP and Proye et al. reported the response of 128 periodontal pockets (3--7 mm) in 10 subjects after a single episode of SRP to give a significant reduction in PI and gingival findings after 1 week.

In the Prodentis group, the combination of SRP+Prodentis demonstrated a significant reduction of PI when compared to SRP and probiotic effects individually, thus the plaque reduction brought about by SRP was enhanced by the use of probiotics. Probiotics and SRP alone were similarly efficacious in plaque reduction. i.e. no difference in mean plaque reduction was observed. Krasse et al. ([@CIT0002]) conducted a study to assess if the probiotic *L. reuteri* could be effective in the treatment of gingivitis and further to evaluate the influence of the probiotic on plaque and the lactobacilli population in the saliva. In their study, *L. reuteri* was efficacious in reducing both gingivitis and plaque in patients with moderate to severe gingivitis.

In the Prodentis group, both the GI score and GBI percentage reduction were significant both with Prodentis alone and in combination with SRP. An interesting observation was that the Prodentis alone group demonstrated a highly significant gingival bleeding reduction as compared to SRP alone. Interestingly, the gingival bleeding reduction by SRP was enhanced by the probiotic. Ma et al. ([@CIT0021]) studied the *in-vitro* effects of live *L. reuteri* on human epithelial cells and found that *L. reuteri* is able to block the TNFα-induced secretion of the pro-inflammatory IL-8, upregulate NGF, and inhibit NF-kB translocation to the nucleus. Twetman et al. ([@CIT0006]) investigated the clinical effect of a chewing gum containing probiotic bacteria on gingival inflammation and the levels of selected inflammatory mediators in gingival crevicular fluid (GCF) in patients with gingivitis. The chewing gums contained two strains of *L. reuteri:* ATCC 55730 and ATCC PTA 5289 (1×10^8^ CFU/gum, respectively). They found that the pro-inflammatory cytokines IL-1β, TNFα, and IL-8 in GCF were reduced by active probiotic treatment, which gives clinical support to the findings by Ma et al. ([@CIT0021]). This may be the proof of a principle for a probiotic approach to combating inflammation in the oral cavity and the findings by Twetman et al. ([@CIT0006]) are confirmed in the present study as evidenced by the reduced gingivitis parameters (GI and GBI).

There was a significant improvement of PPD and CAL in the Prodentis group, which could possibly be due to the significant reduction in the GI and PI. The maximum PPD reduction was observed in those receiving SRP+Prodentis treatment and this reduction (1.31 mm) was more than twice the sum of the SRP alone reduction added to the Prodentis alone reduction (0.49+0.10 mm), suggesting a synergistic effect. An improvement was observed for CAL; SRP alone yielded 0.29 mm, Prodentis yielded 0.17 mm and the combination resulted in a CAL improvement of 1.09 mm. It should be noted that to our knowledge this is the first time that Prodentis or any other probiotic treatment has been shown to improve CAL. In a randomized, double-blinded, placebo-controlled study, Shimauchi et al. ([@CIT0005]) reported a significant improvement of the PI and PPD in the probiotic group (*L. salivarius WB21*), but CAL was not assessed in their study. Moreover, in their clinical setting there was no significant difference between the probiotic and placebo group in the complete set of patients.

It has been observed that there is a substantial *in vitro* variation in the antimicrobial activity of *Lactobacillus* spp. when examined together with several oral microorganisms, including the periodontal pathogens *Aa* and *Pg* ([@CIT0009]). *Aa* strains were the most susceptible species to lactobacilli under the conditions of this experiment. The *in-vitro* effect of probiotics on *Aa*, *Pg*, and *Pi* has been studied ([@CIT0022]), and in the present study the antimicrobial effect of *L. reuteri* Prodentis has been tried for the first time in clinical periodontitis cases. The effect of *L. reuteri* Prodentis on salivary mutans streptococci was not addressed in the present study, but as reported by Caglar et al. ([@CIT0031]), *L. reuteri* significantly reduces mutans streptococci when administered over a 10-day period.

In the present study, the mean CFU reduction of the three assessed pathogens was highest for the combination of SRP+Prodentis followed by Prodentis alone and the size of the reduction was approximately one log unit. The mechanisms of inhibition of periodontal pathogens have not been fully clarified. The inhibitory activity displayed by homofermentative lactobacilli against periodontal pathogens was principally related to their production of acid, not to H~2~O~2~ or bacteriocin production ([@CIT0023]). In the present study, at baseline the 30 chronic generalized periodontitis patients demonstrated the presence of *Aa*, *Pg*, and *Pi*, in accordance with the findings of Socransky et al. ([@CIT0023]). The results obtained by Mousqués et al. ([@CIT0009]) suggest that a single session of SRP is capable of disturbing the proportions of certain bacterial forms in the subgingival periodontal flora, and that it may require approximately 42 days for the proportions to return to baseline levels. Studies designed to determine the effect of SRP on the subgingival microbial flora have consistently reported significant reductions in the percentage of motile microbes and spirochetes ([@CIT0009], [@CIT0022], [@CIT0023]), *Pg* and other Gram negative anaerobic bacteria and a concomitant increase in the percentage of cocci and non-motile bacteria ([@CIT0009], [@CIT0024], [@CIT0025]).

In contrast to the obtained effects of SRP alone on the clinical parameters, we found no significant effects of SRP alone on the microbiological parameters. However, this phenomenon has also been reported by others. Sbordone et al. ([@CIT0026]) evaluated the recolonization patterns of the subgingival microflora of eight adult periodontitis patients after a single session of SRP. Their results indicate that a single session of SRP is clearly insufficient to maintain a healthy subgingival microflora. Mombelli et al. ([@CIT0027]) conducted a study to determine the topographic distribution of *Aa* in patients with adult periodontitis before and after mechanical periodontal treatment (repeated oral hygiene instructions and systematic deep SRP) and found that *Aa* was present in 40% of the samples taken before and in 23% of the samples taken after treatment. Persistence of the organism after thorough debridement of root surfaces has also been reported ([@CIT0027]).

Both the *L. reuteri* strains used in the present study produce the antimicrobial substance reuterin, 3-hydroxypropionaldehyde, within biofilms ([@CIT0028], [@CIT0029]) and it was recently demonstrated that reuterin induces oxidative stress in pathogenic organisms ([@CIT0029]), which accounts for its anti-pathogenic effect. Reuterin is effective against a vast array of intestinal pathogens ([@CIT0030], [@CIT0031]) and the present study suggests a similar effect against selected periodontal pathogens. To our knowledge, the present study is the first of its kind to demonstrate the *in vivo* antimicrobial effect of *L. reuteri* Prodentis in a clinical setting.

The present randomized controlled trial confirms the plaque inhibition, anti-inflammatory, and antimicrobial effects of *L. reuteri* Prodentis. Hence, the *L. reuteri* Prodentis probiotic is suggested as an addition to mechanical debridement and during the maintenance phase of periodontal treatment. Further randomized controlled clinical trials over longer periods are required to build up stronger evidence for probiotic application of *L. reuteri* Prodentis supporting a periodontal treatment protocol.
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